Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million.